Lyell Immunopharma, Inc. — Director's Dealing 2025

May 20, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-05-15

Reporting Person: BRAWLEY OTIS W (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-15	Option (right to buy)	$0.4017	A	130000	Acquired	2035-05-14	Common Stock (130000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	35640	Direct

Footnotes

F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date.